Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
Revenue Growth %: +36.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: +36.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of $128 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UBS Upgrades Eaton Corporation (ETN) to Buy
- Seaport Global Securities Upgrades Asbury Automotive Group (ABG) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
